B+
Bull case
25%
Probability
Target price
$4.20
Analysis reference price unavailable
Analysis 2026-10-26 · RankAlpha Sentiment Codex
FATE
Fate TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$2.70
Analysis reference price unavailable
Analysis 2026-10-26 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$1.10
Analysis reference price unavailable
Analysis 2026-10-26 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-26
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+88.0
Score
AI commentary
Company-source clinical and funding milestones support cautious monitoring, consistent with the positive deterministic prior, but low coverage and absent recent trusted-news, price-reaction, analyst-revision, and measured social data limit conviction. Zero-valued sentiment fields denote unavailable measurements, not neutral readings. Catalyst probabilities and price moves are scenario judgments, not company guidance.
RankAlpha Sentiment Codex - 2026-10-26
Open full AI memoEvidence flagged
small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2027-06-30eventRECLAIM-LN enrollment and renal-response evidenceHigh impact
Fate reported dosing the first patient in its approximately 53-patient Phase 2 FT819 lupus-nephritis trial. Enrollment and eventual Week 26 complete renal-response data could change the thesis; first dosing does not establish efficacy. The date is a monitoring estimate, not company guidance. [#SEC-8K-2026-08-13]
2027-06-30eventFT839 first-patient treatmentHigh impact
Fate reported FDA clearance of the FT839 IND and plans to advance the dual CD19/CD38 CAR T-cell candidate into an autoimmune Phase 1/2 trial. First-patient timing and clinical benefit remain unconfirmed; the date is an illustrative monitoring horizon. [#SEC-8K-2026-08-13]
2027-06-30catalystRECLAIM-LN funding and cash runwayHigh impact
Fate reported a $21 million quarterly decline in cash, cash equivalents and investments and expected runway into 2028. A later 8-K disclosed a $15 million CIRM grant award for RECLAIM-LN, not receipt of all proceeds. Subsequent spending and funding disclosures will test runway durability; the date is a monitoring estimate. [#SEC-8K-2026-08-13] [#8-K-2026-09-28]
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-26 • Updated nightlySource: Internal modelMethodology